Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription

Articles published in
Cancer Lett
    April 2024
  1. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    >> Share

  2. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    >> Share

  3. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    >> Share

  4. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    >> Share

    March 2024
  5. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    >> Share

  6. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    >> Share

  7. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    >> Share

    February 2024
  8. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    >> Share

  9. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    >> Share

  10. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    >> Share

  11. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    >> Share

  12. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    >> Share

  13. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    >> Share

  14. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    >> Share

    January 2024
  15. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    >> Share

  16. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    >> Share

  17. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    >> Share

  18. CHEN L, Xu G, Song X, Zhang L, et al
    A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Cancer Lett. 2024 Jan 16:216635. doi: 10.1016/j.canlet.2024.216635.
    >> Share

    December 2023
  19. ZHONG W, Jian Y, Zhang C, Li Y, et al
    SHC4 orchestrates beta-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation.
    Cancer Lett. 2023 Dec 3:216516. doi: 10.1016/j.canlet.2023.216516.
    >> Share

  20. LEI X, Liao R, Chen X, Wang Z, et al
    IMPA2 promotes basal-like breast cancer aggressiveness by a MYC-mediated positive feedback loop.
    Cancer Lett. 2023 Dec 2:216527. doi: 10.1016/j.canlet.2023.216527.
    >> Share

    November 2023
  21. XIAO Q, Xia M, Tang W, Zhao H, et al
    The lipid metabolism remodeling: A hurdle in breast cancer therapy.
    Cancer Lett. 2023 Nov 28:216512. doi: 10.1016/j.canlet.2023.216512.
    >> Share

  22. WU S, Lu J, Zhu H, Wu F, et al
    A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer.
    Cancer Lett. 2023;581:216508.
    >> Share

  23. GUO H, Tan YQ, Huang X, Zhang S, et al
    Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.
    Cancer Lett. 2023;579:216443.
    >> Share

    August 2023
  24. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    >> Share

    July 2023
  25. CREMER J, Brohee L, Dupont L, Lefevre C, et al
    Acidosis-induced regulation of adipocyte G0S2 promotes crosstalk between adipocytes and breast cancer cells as well as tumor progression.
    Cancer Lett. 2023;569:216306.
    >> Share

  26. TER STEEGE EJ, Doornbos LW, Haughton PD, van Diest PJ, et al
    R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling.
    Cancer Lett. 2023 Jul 3:216301. doi: 10.1016/j.canlet.2023.216301.
    >> Share

    May 2023
  27. REN Z, Xue Y, Liu L, Zhang X, et al
    Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
    Cancer Lett. 2023 May 14:216221. doi: 10.1016/j.canlet.2023.216221.
    >> Share

  28. ZHANG Y, Chen J, Mi D, Ling J, et al
    Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway" [Canc. Lett. (2023) 216142].
    Cancer Lett. 2023 May 6:216195. doi: 10.1016/j.canlet.2023.216195.
    >> Share

    March 2023
  29. ZHANG Y, Chen J, Mi D, Ling J, et al
    Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway.
    Cancer Lett. 2023;560:216142.
    >> Share

  30. DENG L, Liao L, Zhang YL, Hu SY, et al
    MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Cancer Lett. 2023 Mar 10:216124. doi: 10.1016/j.canlet.2023.216124.
    >> Share

  31. MA J, Zhu J, Li J, Liu J, et al
    Enhanced E6AP-mediated ubiquitination of ENO1 via LINC00663 contributes to radiosensitivity of breast cancer by regulating mitochondrial homeostasis.
    Cancer Lett. 2023 Mar 3:216118. doi: 10.1016/j.canlet.2023.216118.
    >> Share

    February 2023
  32. BERG AL, Showalter MR, Kosaisawe N, Hu M, et al
    Cellular transformation promotes the incorporation of docosahexaenoic acid into the endolysosome-specific lipid bis(monoacylglycerol)phosphate in breast cancer.
    Cancer Lett. 2023;557:216090.
    >> Share

  33. GANDULLO-SANCHEZ L, Pandiella A
    An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
    Cancer Lett. 2023;554:216024.
    >> Share

    January 2023
  34. WANG L, Mi D, Hu J, Liu W, et al
    A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.
    Cancer Lett. 2023;555:216049.
    >> Share

    December 2022
  35. BERNARDO G, Le Noci V, Ottaviano E, De Cecco L, et al
    Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness.
    Cancer Lett. 2022;555:216041.
    >> Share

  36. LEE Y, Graham P, Li Y
    Extracellular vesicles as a novel approach for breast cancer therapeutics.
    Cancer Lett. 2022 Dec 12:216036. doi: 10.1016/j.canlet.2022.216036.
    >> Share

    October 2022
  37. XIE XF, Wu NQ, Wu JF, Zhang GL, et al
    CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944.
    >> Share

  38. LUO Y, Tang W, Xiang S, Feng J, et al
    Non-coding RNAs in breast cancer: Implications for programmed cell death.
    Cancer Lett. 2022 Oct 3:215929. doi: 10.1016/j.canlet.2022.215929.
    >> Share

  39. HUANG CP, Liu LC, Chang CC, Wu CC, et al
    Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.
    Cancer Lett. 2022;545:115478.
    >> Share

    September 2022
  40. WANG M, Wei R, Li G, Bi HL, et al
    Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
    Cancer Lett. 2022;549:215923.
    >> Share

  41. LUO M, Li J, Yang Q, Xu S, et al
    N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation.
    Cancer Lett. 2022 Sep 23:215926. doi: 10.1016/j.canlet.2022.215926.
    >> Share

  42. LI T, Zhai D, Zhang M, Ye R, et al
    KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis.
    Cancer Lett. 2022 Sep 8:215904. doi: 10.1016/j.canlet.2022.215904.
    >> Share

  43. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    >> Share

    August 2022
  44. ZHANG T, Huang P
    Response to letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Cancer Lett. 2022 Aug 23:215881. doi: 10.1016/j.canlet.2022.215881.
    >> Share

  45. WANG M, Wei R, Li G, Bi HL, et al
    SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission.
    Cancer Lett. 2022 Aug 20:215871. doi: 10.1016/j.canlet.2022.215871.
    >> Share

  46. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    >> Share

  47. WANG Y, Zhou X, Lei Y, Chu Y, et al
    NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity.
    Cancer Lett. 2022;547:215884.
    >> Share

  48. ZHOU L, Li H, Sun T, Wen X, et al
    HULC targets the IGF1R-PI3K-AKT axis in trans to promote breast cancer metastasis and cisplatin resistance.
    Cancer Lett. 2022 Aug 15:215861. doi: 10.1016/j.canlet.2022.215861.
    >> Share

  49. LIANG Y, Zhou X, Xie Q, Sun H, et al
    CD146 interaction with integrin beta1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells.
    Cancer Lett. 2022;546:215856.
    >> Share

    July 2022
    Predictive biomarkers for personalized medicine in breast cancer.
    Cancer Lett. 2022;545:215828.
    >> Share

  51. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth.
    Cancer Lett. 2022 Jul 5:215800. doi: 10.1016/j.canlet.2022.215800.
    >> Share

    June 2022
  52. ZHAI D, Zhang M, Li Y, Bi J, et al
    LINC01194 recruits NUMA1 to promote ubiquitination of RYR2 to enhance malignant progression in triple-negative breast cancer.
    Cancer Lett. 2022 Jun 21:215797. doi: 10.1016/j.canlet.2022.215797.
    >> Share

  53. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    >> Share

    May 2022
  54. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    >> Share

  55. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    >> Share

  56. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    >> Share

  57. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    CNTF axis to promote progression of brain metastases.&body=SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases. Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726." ALT="Email" TITLE="Email"> --> >> Share

  58. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    >> Share

  59. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
    Cancer Lett. 2022 May 5:215701. doi: 10.1016/j.canlet.2022.215701.
    >> Share

    April 2022
  60. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    >> Share

    March 2022
  61. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    >> Share

  62. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    >> Share

  63. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    >> Share

  64. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    >> Share

    February 2022
  65. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    >> Share

    January 2022
  66. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    >> Share

  67. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    >> Share

  68. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    >> Share

  69. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    >> Share

  70. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    >> Share

    December 2021
  71. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    >> Share

  72. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    >> Share

  73. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    >> Share

    November 2021
  74. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    >> Share

  75. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
    A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
    Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
    >> Share

  76. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
    Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
    Cancer Lett. 2021;520:374-384.
    >> Share

  77. LEE O, Bosland MC, Wang M, Shidfar A, et al
    Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Cancer Lett. 2021;520:255-266.
    >> Share

    October 2021
  78. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
    Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
    >> Share

  79. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
    Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
    Cancer Lett. 2021;517:24-34.
    >> Share

    September 2021
  80. XIA M, Zu X, Chen Z, Wen G, et al
    Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
    Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
    >> Share

  81. LI C, Qiu S, Jin K, Zheng X, et al
    Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Cancer Lett. 2021;523:43-56.
    >> Share

  82. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    >> Share

    June 2021
  83. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016